Pangaea Oncology, a CataloniaBio member, will take over management of the oncology units at four hospitals in Catalonia: Institut Dexeus, Hospital General de Catalunya, Hospital Sagrat Cor and, partially, Teknon. This news stems from an agreement with the Quirónsalud Hospital Group to promote the growth of the biotechnology company in one of its core areas of business: healthcare.

In the areas of pharmaceuticals and pathology labs, Pangaea specialises in liquid biopsies. This technology can pick up traces of cancer in liquid biopsies, like blood or saliva, and has been chosen by the EU for the Elba project (European Liquid Biopsies Academy). This will bring in an additional €247,000 over three years to promote R&D, helping the firm further strengthen its position as a leader in liquid biopsies in Europe.

Pangaea saw turnover of €2.5 million last year and has a staff of 50 employees. In December 2016, the company went public on the Spanish Alternative Equity Market (MAB).

More information is available on the Pangaea Oncology website.

Photo: Javier Rivela, CEO of Pangaea © Pangaea